

2020 Immunisation Update

Prepared and presented by

Sally Edwards
CNC Immunisation Coordinator NSLHD



0

Objectives


- ANI minimum core education requirements
- The National and NSW schedules and changes
- Current vaccine preventable disease activity
- Catch-up immunisation
- Adolescent and adult vaccination
- Other changes for 2020



1

Minimum core education requirements for Authorised Nurse Immunisers

1. NSW Immunisation Authority for Registered Nurses and Midwives
2. Vaccine Storage and management
3. Vaccine administration



Health
Northern Sydney
Local Health District

2

Minimum core education requirements for Authorised Nurse Immunisers

4. NSW Immunisation Schedule
5. Current situation/issues update



Health
Northern Sydney
Local Health District

3

Other required learning:

4. NSW Immunisation Schedule

- Current immunisation schedules - new vaccines/schedule changes
- NSW schedule versus National Immunisation Program Schedule
- Catch-up vaccination – minimum ages, minimum intervals
- School vaccination program schedule and accessing vaccination records
- Maternal influenza and pertussis vaccination
- Neonatal hepatitis B vaccination program
- Health care worker - requirements for staff and students

5. Current situation/issues update

- Current vaccine preventable disease of concern and epidemiology
- Any other issues/concerns
- Contacting the local public health unit
- Useful resources



4

The National Immunisation Program (NIP)

Age	Disease	Vaccine Brand
Childhood vaccination (also see influenza vaccine)		
Birth	Hepatitis B (usually offered in hospital) ¹	HiBax [®] 13 Prevalent or Engix [®] 13 Prevalent
2 months Can be given from 6 weeks of age	Diphtheria, tetanus, pertussis (whooping cough), hepatitis B, polio, pneumococcal (invasive type 6, 9, 14) • Rotarix [®] • Pneumovax [®]	Infanrix [®] hexa Rotarix [®] Prevenar 13 [®]
4 months	Diphtheria, tetanus, pertussis (whooping cough), hepatitis B, polio, pneumococcal (invasive type 6, 9, 14) • Rotarix [®] • Pneumovax [®]	Infanrix [®] hexa Rotarix [®] Prevenar 13 [®]
6 months	Diphtheria, tetanus, pertussis (whooping cough), hepatitis B, polio, pneumococcal (invasive type 6, 9, 14)	Infanrix [®] hexa
Additional dose for children with specified medical risk conditions²	• Pneumococcal	Prevenar 13 [®]
12 months	Meningococcal ACWY, Measles, mumps, rubella • Pneumococcal	Menax [®] MM 81 [®] 8 or ProQua [®] Prevenar 13 [®]
18 months	Hemophilus influenzae (type b) (Hib), Measles, mumps, rubella, varicella (chickenpox) • Diphtheria, tetanus, pertussis (whooping cough)	ActiHib [®] Priorix Tetra [®] or ProQua [®] Infanrix [®] or Triptacel [®]
4 years	Diphtheria, tetanus, pertussis (whooping cough), polio	Infanrix [®] IPV or Quadbra [®]
Additional dose for children with specified medical risk conditions²	• Pneumococcal ³	Pneumovax 23 [®]
Adolescent vaccination (also see influenza vaccine)		
12-13 years (school programs) ⁴	Human papillomavirus (HPV) ⁵ • Diphtheria, tetanus, pertussis (whooping cough)	Gardasil9 [®] Boostrix [®]
16-18 years (school programs) ⁴	Meningococcal ACWY	Menax [®]

Age	Disease	Vaccine brand
Adult vaccination (also see influenza vaccine)		
70 years and over	• Pneumococcal	Prevenar 13 [®]
70-79 years¹	• Shingles (Zostavax) ²	Zostavax [®]
Pregnant women	• Pertussis (whooping cough) ³	Boostrix [®] or Adacel [®]
Annual influenza vaccination⁴		
Children 6 months to less than 5 years of age		
People 6 months and over with specified medical risk conditions		
Pregnant women		

¹ Influenza B vaccine should be given to all infants as soon as possible after birth. The greatest benefit is if given within 24 hours, and must be given within 7 days.

² Influenza vaccine (P13) should be given to people 65 years of age and over, and to people 65 years of age and over with specified medical risk conditions.

³ Risk conditions are specified in the ATSDU clinical advice on shingles in vaccine recommendations and listing for people with risk conditions from 1 July 2020.

⁴ Influenza for most of January, or just before, followed by second dose in February or March 3 years later.

⁵ Catch-up doses in primary health centres for school-grade eligible for vaccination.

⁶ Clinicians should refer to the ATSDU clinical advice on shingles in vaccine recommendations and listing for people with risk conditions from 1 July 2020.

⁷ All people aged 70 years and over with a free year catch-up program for people aged 70-79 years of age on 30 October 2020.

⁸ Single doses recommended each pregnancy, ideally between 20-30 weeks but may be given up until delivery.

⁹ Refer to annual ATSDU advice on seasonal influenza vaccines.

All people aged less than 20 years are eligible for free catch-up vaccines. The number and range of vaccines and doses that are eligible for NIP-funded catch-up is outlined for people aged less than 10 years and those aged 10-19 years. Refer to NIP catch-up fact sheets. Adult refugees and humanitarian entrants are eligible for free catch-up vaccines.

For more information

Health and Community Services
 New South Wales
 Australian Capital Territory
 New South Wales
 Northern Territory
 Queensland
 South Australia
 Tasmania
 Victoria
 Western Australia

Contact Number
 (02) 5224 9800
 (08) 606 9100
 (08) 9552 8544
 (07) 4621 05 4225 916
 1800 232 272
 1800 671 758
 1800 982 028
 (08) 9221 1072

<https://www.health.gov.au/resources/publications/national-immunisation-program-schedule-for-all-non-indigenous-people>

5

The National Immunisation Program (NIP)

National Immunisation Program Schedule 1 July 2020
For all Indigenous people

Age	Disease	Vaccine Brand
Indigenous children (also see influenza vaccine)		
Birth	Hepatitis B (usually offered in hospital) ¹	HiB-Hib 4 Pediatric or Engerix B ² Pediatric
2 months Can be given from 8 weeks of age	Diphtheria, tetanus, pertussis (whooping cough), hepatitis B, polio, Haemophilus influenzae type B (Hib) ³ • Rotavirus ⁴ • Pneumococcal • Meningococcal B	Infanrix ⁵ Hexa Rotarix ⁶ Prevenar 13 ⁷ Bexsero ⁸
4 months	Diphtheria, tetanus, pertussis (whooping cough), hepatitis B, polio, Haemophilus influenzae type B (Hib) ³ • Rotavirus ⁴ • Pneumococcal • Meningococcal B	Infanrix ⁵ Hexa Rotarix ⁶ Prevenar 13 ⁷ Bexsero ⁸
6 months	Diphtheria, tetanus, pertussis (whooping cough), hepatitis B, polio, Haemophilus influenzae type B (Hib) ³	Infanrix ⁵ Hexa
Additional dose for children in WA, NT, SA, Qld and children with specified medical risk conditions⁹	Pneumococcal	Prevenar 13 ⁷
Additional dose for children with specified medical risk conditions⁹	Meningococcal B	Bexsero ⁸
12 months	Meningococcal ACWY ¹⁰ • Measles, mumps, rubella • Pneumococcal • Meningococcal B	Menomax ¹¹ MMR1 ¹² (or ProQuad ¹³) Prevenar 13 ⁷ Bexsero ⁸
18 months	Haemophilus influenzae type B (Hib) ³ • Measles, mumps, rubella, varicella (chickenpox) • Diphtheria, tetanus, pertussis (whooping cough)	Acti-Hib ¹⁴ ProQuad ¹³ or ProQuad ¹³ Infanrix ⁵ or Trippax ¹⁵
Additional vaccine for children in WA, NT, SA, Qld¹⁶	Hepatitis A	Vaxig ¹⁷ Pediatric
4 years	Diphtheria, tetanus, pertussis (whooping cough), polio	Infanrix ⁵ IPV or Quadrax ¹⁸
Additional dose for children in WA, NT, SA, Qld and children with specified medical risk conditions⁹	Pneumococcal ¹⁹	Prevenar 23 ²⁰
Additional vaccine for children in WA, NT, SA, Qld¹⁶	Hepatitis A	Vaxig ¹⁷ Pediatric

National Immunisation Program Schedule 1 July 2020
For all Indigenous people

Age	Disease	Vaccine Brand
Indigenous adolescents (also see influenza vaccine)		
12-13 years (School program) ¹	• Human papillomavirus (HPV) ² • Diphtheria, tetanus, pertussis (whooping cough)	Gardasil ³ Boostrix ⁴
14-16 years (School program) ¹	• Meningococcal ACWY	Menomax ⁵
Indigenous adults (also see influenza vaccine)		
90 years and over⁶	• Pneumococcal	Prevenar 13 ⁷ and Prevenar 23 ⁸
70-79 years	• Shingles (herpes zoster)	Zostavax ⁹
Pregnant women	• Pertussis (whooping cough) ¹⁰ • Influenza ¹¹	Boostrix ⁴ or Adacel ¹²
Funded annual influenza vaccination		
All Aboriginal and Torres Strait Islander people 6 months and over		

1. Priority 1. Available through the general practitioner or school immunisation clinic only. The general practice 8.8 program until 24 hours, and must be given within 7 days.
2. Recombinant vaccine. First dose must be given by 18 months of age, the second dose by 24 months of age.
3. Risk conditions are specified in the NIP information pack or changes to vaccine recommendations according to people with risk conditions (last July 2020)
4. First dose of the 2-dose Gardasil A vaccination schedule. If not previously received a dose. The second dose is now scheduled at 4 years.
5. A minimum 10-week interval between doses. Followed by a second dose of 23PPV at least 8 years later.
6. Not used if previously received 3 doses (first dose at age 10 months or used 6 months apart)
7. Contact your state or territory health service for the correct vaccine supply for vaccination.
8. Dose: 0.5mL (single dose) to age 60 and over, 2 doses, 1st 15 years, 6 months minimum interval, 2 doses, 1st 15 years and then have certain medical conditions - 0.5 mL (single dose) children 16-64 years (total of 2 doses) at 0-15 years and 16-64 years with certain medical risk factors.
9. Administer a dose of Zostavax before the first dose of 23PPV. 10 months (at 2-10 months recommended). The second dose of 23PPV at least 5 years after the first dose and after 10 years with certain medical risk conditions for people aged 70-79 years and over. 10 October 2020.
10. Single dose recommended each pregnancy, ideally between 30-32 weeks but may be given pre- or post-natal.
11. Single dose recommended each pregnancy, ideally between 30-32 weeks but may be given pre- or post-natal.
12. Note: In general 23PPV adults on complete influenza vaccines.

All people aged less than 20 years are eligible for free catch-up vaccines. The number and range of vaccines and doses that are eligible for NIP funded catch-up is different for people aged less than 10 years and those aged 10-19 years. Refer to NIP catch-up fact sheets. Adult, teenager and immunisation services are eligible for free catch-up vaccines.

1. Meningococcal B vaccine catch-up is available for all Aboriginal and Torres Strait Islander children 2 years of age and over from 1 July 2020.
2. Refer to the Australian Government Department of Health website for more information.
3. People aged 16 months and over with specified medical risk conditions for pneumococcal vaccine require a dose of 23PPV or a booster dose of 23PPV.
4. Refer to the Australian Government Department of Health website for more information.
5. NIP for eligibility who is the 23PPV (second dose) or a booster dose of 23PPV.
6. The NIP also funds vaccines for people of all ages with the following specified medical risk conditions (see the Department of Health website for more information):
• immunocompromised (HIV, HIV/AIDS, organ transplants, and HIV if required immunosuppressive therapy)
• chemotherapy treatment with cytotoxic drugs (BMT, HSCT)
• cancer and haem and haematology (BMT, HSCT, splenectomy)
• other additional immunisation programs specific to your State or Territory.

For more information
Health.gov.au/immunisation
New South Wales
Northern Territory
Queensland
South Australia
Tasmania
Victoria
Western Australia

Contact Number
020 554 9800
080 086 000
08 9922 2044
13 HEALTH (13 4325 86)
080 242 272
1800 671 738
020 662 026
08 9231 102

<https://www.health.gov.au/resources/publications/national-immunisation-program-schedule-for-all-aboriginal-and-torres-strait-islander-people>

6

NSW Immunisation Schedule

Funded July 2020



CHILDHOOD VACCINES			
AGE	DISEASE	VACCINE	INFORMATION
Birth	Hepatitis B	HiB-VR II OR ENGERIX B (IM)	Within 7 days of birth (ideally within 24 hours)
6 weeks	Diphtheria, tetanus, pertussis, Haemophilus influenzae type B, hepatitis B, polio • Pneumococcal • Rotavirus • Meningococcal B (Aboriginal children only)	INFANRIX HEXA (IM) OR PRIORIX 13 (IM) OR ROTARIX (Oral) OR BEXSERO (IM)	ROTARIX: Dose 1 limited to 6-14 weeks of age BEXSERO: Prophylactic paracetamol recommended. Catch up available for Aboriginal children <2 until 30/06/2023
4 months	Diphtheria, tetanus, pertussis, Haemophilus influenzae type B, hepatitis B, polio • Pneumococcal • Rotavirus • Meningococcal B (Aboriginal children only)	INFANRIX HEXA (IM) OR PRIORIX 13 (IM) OR BEXSERO (IM)	ROTARIX: Dose 2 limited to 10-14 weeks BEXSERO: Prophylactic paracetamol recommended. Catch up available for Aboriginal children <2 until 30/06/2023
6 months	Diphtheria, tetanus, pertussis, Haemophilus influenzae type B, hepatitis B, polio	INFANRIX HEXA (IM)	Children 16 months with at risk conditions for IPV are recommended to receive an additional dose of PREVENAR 13 - see AHP ¹ Aboriginal children <16 months with certain at risk conditions may require an additional dose of Bexsero - see AHP ¹
12 months	Meningococcal ACWY ² • Pneumococcal • Measles, mumps, rubella • Meningococcal B (Aboriginal children only)	NIMENRIX (IM) OR PREVENAR 13 (IM) OR PRIORIX (IM or SC) OR BEXSERO (IM)	Bexsero: Prophylactic paracetamol recommended. Catch up available for Aboriginal children <2 until 30/06/2023
18 months	Diphtheria, tetanus, pertussis • Measles, mumps, rubella, varicella • Haemophilus influenzae type B	INFANRIX OR TETRACEL (IM) OR PRIORIX TETRA OR PROQUAD (IM or SC)	
4 years	Haemophilus influenzae type B Diphtheria, tetanus, pertussis, polio	ACT-HIB (IM or SC) OR INFANRIX IPV OR QUADRACEL (IM)	Children with at risk conditions for BCI are recommended to receive an additional dose of 23PPV/23VAX 23 - see AHP ¹

AT RISK GROUPS, ADOLESCENTS AND ADULTS			
AGE/GROUP	DISEASE	VACCINE	INFORMATION
All people with asplenia, hypoplenia, complement deficiency and treatment with eculizumab or hypoplenia	Meningococcal ACWY	NIMENRIX (IM)	See AHP ¹ for required doses and timing
	Meningococcal B	BEXSERO (IM)	Additional groups are recommended to receive these vaccines but these are not funded
>5 years with asplenia or hypoplenia	Haemophilus influenzae type B	ACT-HIB (IM or SC)	If incompletely vaccinated or not vaccinated in childhood
Year 7	Diphtheria, tetanus, pertussis Human papillomavirus	BOOSTRIX (IM) OR GARDASIL 9 (IM)	
Year 10	Meningococcal ACWY	NIMENRIX (IM)	
Pregnant	Influenza Pertussis	INFLUENZA OR BOOSTRIX OR ADACEL (IM)	Influenza: Any trimester Pertussis: each pregnancy between 30-35 weeks
Aboriginal people <90 years	Pneumococcal	PREVENAR 13 (IM) then PNEUMOVAX 23 (IM)	Prevenar 13: 150 years Pneumovax 23: 2-12 months later Pneumovax 23: at least 6 years later
70 years	Pneumococcal	PREVENAR 13 (IM) OR ZOSTAVAX (SC)	Pneumococcal funded for people >70 Zoster: Catch up available for 71-79 year olds until 31/03/2021

People with at risk conditions for IPV: See the online AHP¹ for conditions recommended to receive PREVENAR 13 and PNEUMOVAX 23

The NSW Immunisation Schedule



Health
Northern Sydney
Local Health District

<https://www.health.nsw.gov.au/immunisation/Publications/nsw-immunisation-schedule.pdf>

7

Additional Commonwealth funded vaccines

- Ongoing catch-up for 10-19 y.o.

• Dtpa	• Hep B
• Polio	• HPV (age dependent)
• MMR	• Meningococcal (age dependent)
• Varicella	

- Ongoing catch-up for refugees and humanitarian entrants aged 20 years and over.

• Dtpa	• Hep B
• Polio	• Varicella
• MMR	

https://www.health.nsw.gov.au/immunisation/Pages/gp_catchup.aspx



8

Additional NSW funded vaccines

- Hepatitis B

- Aboriginal people	- Men who have sex with men
- Household contacts	- Injecting drug users
- Immunocompromised	- Sex workers
- People with HIV or Hep C	- Clients of sexual health clinics

- HPV

- Refugees 20 – 26 years of age

- MMR

- Unvaccinated people born during or after 1966

- Rubella seronegative post natal women

- Rabies Post Exposure Prophylaxis

https://www.health.nsw.gov.au/immunisation/Pages/gp_catchup.aspx



9

Schedule FAQs

Who are entitled to the free catch-up vaccines?

- Eligibility for free vaccines under the NIP is linked to eligibility for Medicare benefits. Must be:
 - an Australian citizen
 - a New Zealand citizen
 - an Australian permanent resident
 - applying for permanent residency
 - covered by a ministerial order.



AUSTRALIAN NIP CHANGES

- Which diseases do the changes affect?
 - Pneumococcal
 - Meningococcal B
 - Meningococcal ACWY
 - Haemophilus influenzae type b (HIB)
 - Hepatitis A - ONLY Aboriginal children in NT, WA, SA and QLD

12

Pneumococcal

- Pneumococcal (Prevenar 13 and Pneumovax 23)
 - ✓ At risk groups – all ages,
 - ✓ Aboriginal people ≥ 50 years of age (without at risk conditions),
 - ✓ Non-Aboriginal people ≥ 70 years of age (without at risk conditions),
 - ✓ Aboriginal children ONLY in NT, WA, SA and QLD

13

At Risk Groups

- Category A and Category B lists replaced with single list of risk conditions.
- All listed conditions are recommended to receive pneumococcal vaccination - only funded for some.
- Pneumovax 23 now limited to 2 lifetime doses.

<https://www.health.gov.au/resources/publications/national-immunisation-program-pneumococcal-vaccination-schedule-from-1-july-2020-clinical-decision-tree-for-vaccination-providers>

Table 1. Updated list of risk conditions for pneumococcal vaccine recommendations and their eligibility for funding under the National Immunisation Program (NIP)

Risk condition	Eligibility for NIP funding	
	<5 years of age	≥5 years of age
Previous episode of invasive pneumococcal disease	✓	✓
Functional or anatomical asplenia, including		
– sickle cell disease or other haemoglobinopathies	✓	✓
– congenital or acquired asplenia (for example, splenectomy) or hyposplenia	✓	✓
Immunocompromising conditions, including		
– congenital or acquired immune deficiency, including symptomatic IgG subclass or isolated IgA deficiency	✓	✓
– haematological malignancies	✓	✓
– solid organ transplant	✓	✓
– haematopoietic stem cell transplant	✓	✓
– HIV infection	✓	✓
– immunosuppressive therapy, where sufficient immune reconstitution for vaccine response is expected; this includes those with underlying conditions requiring but not yet receiving immunosuppressive therapy	✓	✓
– non-haematological malignancies receiving chemotherapy or radiotherapy (currently or anticipated)		
Proven or presumptive cerebrospinal fluid (CSF) leak, including		
– cochlear implants	✓	✓
– intracranial shunts	✓	✓
Chronic respiratory disease, including		
– suppurative lung disease, bronchiectasis and cystic fibrosis	✓	✓
– chronic lung disease in preterm infants	✓	✓
– chronic obstructive pulmonary disease (COPD) and chronic emphysema	✓	✓
– severe asthma (defined as requiring frequent hospital visits or the use of multiple medications)		
– interstitial and fibrotic lung disease		
Chronic renal disease		
– relapsing or persistent nephrotic syndrome	✓	✓
– chronic renal impairment – eGFR <30 mL/min (stage 4 or 5 disease)	✓	✓
Cardiac disease, including		
– congenital heart disease	✓	✓
– coronary artery disease	✓	✓
– heart failure	✓	✓
Children born less than 28 weeks gestation	✓	✓
Trisomy 21	✓	✓
Chronic liver disease, including		
– chronic hepatitis		
– cirrhosis		
– biliary atresia		
Diabetes		
Smoking (current or in the immediate past)		
Harmful use of alcohol (defined as consuming on average ≥60 g of alcohol (8 Australian standard drinks) per day for males and ≥40 g of alcohol (4 Australian standard drinks) per day for females)		
* Funded under the NIP for eGFR ≥15 mL/min only (including patients on dialysis). Individual conditions listed beneath or those that are similar based on clinical judgment.		
Note: All children and adults with above conditions are recommended to receive additional pneumococcal vaccine doses. However, they are only funded under the NIP for those with the shaded conditions.		
All information in this fact sheet is correct as of June 2020. REPORT all vaccinations to the Australian Immunisation Register (AIR).		

State and territory health department contact numbers

NSW 13 22 212
VIC 13 22 212
QLD 13 22 212
SA 13 22 212
WA 13 22 212
NT 13 22 212
ACT 13 22 212
Tasmania 13 22 212
Contact your local Public Health Unit



14

Children ≤ 12 months with at risk conditions

****Does not affect the routine childhood pneumococcal schedule****

- For children with risk conditions:
 - ✓ Additional dose of Prevenar 13 at 6 months (or at diagnosis if diagnosed 6-11 months of age)
 - ✓ Then receive Pneumovax 23 at 4 years of age
 - ✓ Additional dose Pneumovax 23 least 5 years later



Health
Northern Sydney
Local Health District

15

Anyone > 12 months with at risk conditions

- ✓ Receive Prevenar 13 at diagnosis.
- ✓ Then receive Pneumovax 23: 2-12 months later or ≥ 4 y.o. (whichever is later)
- ✓ Additional dose of Pneumovax 23 at least 5 years later

Catch up tables available in the online handbook

Aboriginal people ≥ 50 years of age (without risk factors)

- ✓ Prevenar 13 at ≥ 50 years of age
- ✓ Pneumovax 23: 2-12 months later
- ✓ Final dose Pneumovax 23: minimum 5 years later

If they have previously received Pneumovax 23:

- ✓ Still give Prevenar 13 - wait 12 months after Pneumovax 23

If second dose required: Give final dose Pneumovax 23: 12 months after Prevenar 13 or 5 years after previous dose of Pneumovax 23 (whichever is later)

All individuals ≥ 70 years of age (without risk factors)

****Pneumovax 23 at 65 years is no longer recommended or funded****

- ✓ Prevenar 13 at ≥ 70 years of age
- ✓ No time limited catch up
- ✓ Anyone ≥ 70 years of age on 1 July 2020 are eligible for a single funded dose of Prevenar 13.
- ✓ If they already had Pneumovax 23 at 65, should still receive Prevenar 13 - leave 12 months between doses



National Immunisation Program
A joint Australian, State and Territory Government initiative

National Immunisation Program
Pneumococcal vaccination schedule from 1 July 2020

Clinical decision tree for vaccination providers

From 1 July 2020, there are changes to the National Immunisation Program (NIP) pneumococcal vaccination schedule.

This decision tree should be read in conjunction with the NIP pneumococcal vaccination schedule from 1 July 2020 clinical advice for vaccination providers and the **Australian Immunisation Handbook**.

Figure 1. NIP funded pneumococcal vaccine schedule from 1 July 2020

The list of risk conditions is set out in **Table 1** over the page. Some of these conditions are eligible for NIP funded doses of pneumococcal vaccines.

Universal childhood schedule All non-Indigenous children Aboriginal and Torres Strait Islander children living in ACT, NSW, Tas and Vic	At risk children <12 months All children with risk conditions Aboriginal and Torres Strait Islander children living in NT, Qld, SA and WA	Children >12 months, adolescents and adults of any age diagnosed with a risk condition	Aboriginal and Torres Strait Islander adults without a risk condition	Non-Indigenous adults without a risk condition
13vPCV at age 2 months	13vPCV at age 2 months	13vPCV at diagnosis	13vPCV at age 50 years	13vPCV at age 70 years
13vPCV at age 4 months	13vPCV at age 4 months	23vPPV / 2-12 months later, or at age 34 years, whichever is later	23vPPV / 2-12 months later	
13vPCV at age 12 months	13vPCV at age 12 months	23vPPV at least 5 years later	23vPPV at least 5 years later	
	23vPPV at age 4 years			
	23vPPV at least 5 years later			

<https://www.health.gov.au/resources/publications/national-immunisation-program-pneumococcal-vaccination-schedule-from-1-july-2020-clinical-decision-tree-for-vaccination-providers>

Schedule FAQs

What immunisation should a patient who turned 70 on 15 July, 2020 receive?

- Influenza (≥ 65 years vaccine)
- Pneumococcal (Prevenar 13)
- Zoster (Zostavax)

20

Meningococcal

- Meningococcal B (Bexsero)

- ✓ Aboriginal children
- ✓ Certain at risk groups

Not recommended for NIP listing for anyone else due to uncertainties regarding the magnitude of clinical effectiveness and lack of herd protective effects.

- Meningococcal ACWY (Nimenrix)

- ✓ Certain at risk groups

21

Meningococcal B - Aboriginal children

- Bexsero (MenB) - now included on the routine childhood schedule for Aboriginal children at 6 weeks, 4 months and 12 months
- Catch up funded for children < 2 years of age until 30 June 2023
- Prophylactic paracetamol recommended prior and post vaccination
- Not required to receive family benefits i.e. No Jab, No Pay/Play
- Additional dose (age dependent) for those with:
 - Asplenia or hyposplenia
 - Complement deficiency
 - Treatment with eculizumab
 - HIV
 - Haematopoietic stem cell transplant



22

Meningococcal B - At risk groups

- At risk conditions that are now funded to receive MenB (Bexsero) vaccine:
 - Asplenia
 - Hyposplenia
 - Complement deficiency
 - Treatment with Eculizumab
- See online Australian Immunisation Handbook for age appropriate courses
- Still recommended for people with HIV and Haematopoietic stem cell transplant but **not funded under the NIP** (unless Aboriginal children < 2 years of age).



23

Meningococcal ACWY - Nimenrix

- At risk conditions that are now funded to receive Meningococcal ACWY (Nimenrix) vaccine:
 - Asplenia
 - Hyposplenia
 - Complement deficiency
 - Treatment with Eculizumab
- See online Australian Immunisation Handbook for age appropriate courses
- Those in these categories with ongoing risk are eligible for boosters - advice in the online AIH

24

Haemophilus influenzae type b


- A single dose of Act-HIB funded for people > 5 years of age with:
 - Asplenia
 - Hyposplenia
- ✓ Single Hib dose is required if the person was not vaccinated in infancy or was incompletely vaccinated.
- ✓ Booster doses of Hib vaccine are not required
- Still recommended for people who receive haematopoietic stem cell transplants but **not funded under the NIP**

25

Cold chain and vaccine storage

NSW Vaccine Centre

1300 656 132



- Place an order
- View your order history
- Amend Delivery Address
- View Contact Details
- User Guide
- Logout

Logged in as:
150039/0001
NORTHERN SYDNEY
PHU

To contact your Public Health Unit please call 1300 656 055.

Last logged in:
Monday, 29 July 2019
1:13:43 PM

Home > Authorised Practice Provider Declaration

Authorised Practice Provider Declaration

Need to be able to answer 'yes' to all declarations

In order to receive Government-funded vaccines, I declare that:


- All vaccines will be administered according to NSW Health's vaccine eligibility criteria (previous page) and the NSW Immunisation Program Schedule Yes No
- Each vaccine dose administered in this practice will be notified to the Australian Immunisation Register Yes No
- This facility complies with cold chain Guidelines - Strive for Five (3rd edition) **Includes having a vaccine specific fridge** Yes No
- Vaccine fridge temperatures (current, minimum and maximum) are checked and recorded twice daily, thermometer reset and all records are kept according to medico-legal requirements. Yes No
- The vaccine fridge temperature is continuously monitored with a separate electronic data logger, set to record at 5 minute intervals and the data logging report is downloaded, saved to medico-legal requirements and reviewed once a week and/or if there is a min/max reading of below +2°C or above +8°C. Yes No
- In the event of a cold chain breach, I will call my local Public Health Unit on 1300 066 055 for advice before taking any further action. Yes No
- The vaccine fridge(s) temperature has/have been between +2°C and +8°C since the last vaccine order (this excludes excursions up to +12°C for less than 15 minutes when opening the fridge and excludes cold chain breaches that have already been notified to the Public Health Unit). Yes No
- At least one staff member has successfully completed the NSW Health Vaccine Storage and Cold Chain Management online training module. Yes No

CONTINUE

26

Vaccine Storage and Cold Chain Management

Menu About Resources Help



Vaccine Storage and Cold Chain Management


- This module contains audio, please make sure your speakers are turned on or your headphones are plugged in.
- Click the **Next >** button to continue.

1 of 67

https://nswhealth.seertechsolutions.com.au/public_content/HETICP/HETI/CCMWebv3/story_html5.html

27

Vaccine storage



- Use trays and uncovered containers to organise boxes
- Position with enough space between them to allow air flow
- Do not overstock – order only what is needed for the month
- Don't transport vaccines between vaccine account locations
- Do not remove from original packaging - UV sensitive

28

Schedule FAQs

A mother bought her 5 week and 6 day old baby in for their 6 week vaccinations. Can you give them early?


- **No. Never bring the 6 week vaccinations forward.**
- The vaccines are registered for use from 6 weeks of age, no earlier.

29

Vaccine Preventable Diseases



30



- Causes significant worldwide morbidity and mortality
- > 350 million people worldwide with chronic infection
- Infected more than a third of the world's population
- More than one million deaths worldwide every year
- Over 2000 new cases annually in NSW
- ~ 230,000 with chronic infection in Au

31

Immunisation control strategy

- Birth dose offered to all neonates - 95% in NSLHD.
- Given within the first seven days of life (preferably within 24 hours).
- **Cannot be caught up**
- Protects against vertical (mother to baby) and horizontal transmission (others to baby).
- Primes B cell memory in readiness for next 3 doses given at 6 weeks, 4 months & 6 months.
- 1st, 2nd and 3rd doses given at 6 weeks, 4 months and 6 months as per the schedule - 96.5% @ 12 months in NSLHD.

HBsAg positive mothers

- Babies given immunoglobulin within 12 hours of birth + vaccine - 100% in NSLHD.
- 1st, 2nd and 3rd doses are given as per the schedule.
- Follow-up of mothers and babies by PHU
 - timeliness of vaccination
 - HBsAg and anti-HBs checked 3 – 12 months after Hep B course is completed (not before 9/12 of age – due to birth dose of HBIG).

Importance of early protection against Hep B

	Infected as adults	Infected as infants
Symptoms	30 - 50% symptomatic	Usually asymptomatic
Recovery	Most recover without treatment	Usually persistent
Likelihood of chronic infection	5 – 10%	90% in infants 30% in children

- Children infected at birth:
 - More likely to develop chronic infection.
 - More likely to develop advanced liver disease.

34

Pertussis (whooping cough)



- Bacterial respiratory infection caused by *Bordetella pertussis*.
- Infectious for 3 weeks after symptom onset or 5 days ABs.
- Rates peak every 3 - 4 years in Australia.
- Infants < 6 months old at greatest risk.
- Under recognised in adults and older children.

35


Immunisation control strategies

- Primary DTPa :
 - 6 weeks
 - 4 months
 - 6 months
- Booster DTPa:
 - 18 months
 - 4 years
 - Adolescence
- Maternal dTpa
- Vaccination 10 yearly for adults at risk

36

Pertussis Notifications in NSW


Pertussis notifications in NSW residents, by month of disease onset and age group. January 2014 to March 2020.



37

Pertussis notifications by age and gender

Pertussis notifications in NSW residents, by five year age group and gender. March 2019 to February 2020



<https://www.health.nsw.gov.au/Infectious/Pages/data.aspx>

38

Measles



- Highly contagious viral illness.
- Common complications: otitis media, pneumonia and bronchitis.
- Severe complications occurs in 1-3/1000 children and can be fatal.
- Estimated to cause 2.6 million deaths a year before the vaccine
- 142 000 measles deaths globally in 2018, mostly in children < 5 yrs.

39

MEASLES OUTBREAKS IN AUSTRALIA

Measles in Australia

- Australia measles free since 2014.
- Almost all cases seen are imported from overseas.
- Children aged < 12 months and Australians in their 20's – early 50's at greater risk.
- 2019 – 59 cases in NSW
- Increase in cases due to global and neighbouring outbreaks.
- 2020 – 11 cases in NSW Jan/Feb

40

Immunisation control strategies


Almost entirely preventable with 2 doses of vaccine.

- Two funded doses MMR vaccination:
 - From 12 months on NIP
 - All unvaccinated people born during or after 1966
 - Rubella seronegative post natal women
- Early vaccination from 6 months of age in special circumstances
- 93.71% of 2 y.o. are vaccinated for measles in Australia


41

Measles notifications in NSW

Measles notifications in NSW residents, by month of disease onset and age group. January 2016 to March 2020.



<https://www.health.nsw.gov.au/Infectious/Pages/data.aspx>




Health
Northern Sydney
Local Health District


42

Measles notifications by age and gender

Measles notifications in NSW residents, by five year age group and gender. March 2019 to February 2020



<https://www.health.nsw.gov.au/Infectious/Pages/data.aspx>



Health
Northern Sydney
Local Health District

43

Global situation



- Globally ~ 300% increase in 2019.
- All regions of the world experienced sustained rises in cases.
- Samoa in a state of emergency at the beginning of 2020 due to an outbreak – over 5000 cases and 80 deaths
- Concurrent outbreaks in NZ, Tonga, American Samoa and Fiji
- In 2019 WHO estimates only 86% children have received the first dose of measles vaccine and 69% the second.

44

Schedule FAQs

How soon before the 12 month milestone can MMR be administered?

- Only bring forward in special circumstances i.e. travel, outbreak management.
- Now registered from 6 months of age (needs repeating).
- Can be administered from 11 months without repeating.
- If administered before 11 months of age, repeat at 12 months of age.

45



Meningococcal Disease

- Bacterial infection caused by meningococcus bacteria
- Highest incidence in < 2 years and 15-19 years
- 13 serogroups, disease most commonly due to A, B, C, W & Y
- Men B and W - most dominant strains in Australia
- Men B - most common in children (case fatality 5%)
- Men W – widespread across all age groups (case fatality 9.3%)




Health
Northern Sydney
Local Health District

46

Meningococcal notifications in NSW

Meningococcal disease (B, C, Not specified, W, Y) notifications in NSW residents, by month of disease onset. January 2016 to March 2020.




<https://www.health.nsw.gov.au/Infectious/Pages/data.aspx>



Health
Northern Sydney
Local Health District

47

Meningococcal B by age and gender




<https://www.health.nsw.gov.au/Infectious/Pages/data.aspx>



Health
Northern Sydney
Local Health District

48

Meningococcal W by age and gender




<https://www.health.nsw.gov.au/Infectious/Pages/data.aspx>



Health
Northern Sydney
Local Health District

49


Meningococcal Y by age and gender



<https://www.health.nsw.gov.au/Infectious/Pages/data.aspx>



50



<https://www.health.nsw.gov.au/Infectious/Pages/data.aspx>



51

Immunisation control strategies

- 2003 – 2018: Men CCV at 12 months
- From 2017: 4vMenCV in adolescent program
- 1 July 2018: 4vMenCV at 12 months
- 1 July 2020: Men B (MenBCV) added for Aboriginal children < 2 and risk medical conditions.



Men ACWY vaccination – funded groups

Funded for:

- Children at 12 months of age
- Catch-up of children < 10 years of age who haven't received a MenCCV vaccine.
- Adolescents 15 - 19 years of age.

NeisVac-C (MenCCV) – used in catch-up for children 10 - 14 years of age.

Schedule FAQs


How soon before the 12 month milestone can Nimenrix be given without needing to be repeated?

- Only bring forward in special circumstances i.e. travel, outbreak management.
- Can be administered from 11 months of age with no further doses required.
- If given before 11 months of age, further dose of meningococcal will be required at 12 months of age or 8 weeks since last 4vMenCV, whichever is greater.

54



COVID-19




- Viral infection caused by a new strain of coronavirus.
- Spread from person to person via infected respiratory droplets.
- Still much to learn - epidemiological and clinical investigations ongoing.
- Australia: 15,582 cases, 176 deaths
 - ~ 1.4% crude case fatality rate
- Globally: > 17,000,000 cases, > 669,000 deaths
 - ~ 4.1% crude case fatality rate

55

COVID-19 cases by age group and sex

This graph shows the number of confirmed COVID-19 cases for males and females by age group since 22 January 2020.

Source: NNDSS data 29/7/2020




<https://www.health.gov.au/news/health-alerts/novel-coronavirus-2019-ncov-health-alert/coronavirus-covid-19-current-situation-and-case-numbers>

56

COVID-19 deaths by age group and sex

This graph shows the number of COVID-19 deaths for males and females by age group since 22 January 2020.

Source: NNDSS data 29/07/2020



<https://www.health.gov.au/news/health-alerts/novel-coronavirus-2019-ncov-health-alert/coronavirus-covid-19-current-situation-and-case-numbers>

57

COVID-19 vaccine progress

- Twenty-four vaccine candidates currently in clinical evaluation.
- Four vaccines currently in Phase 3 trials:
 - Sinovac
 - Wuhan Institute of Biological Products/Sinopharm
 - Beijing Institute of Biological Products/Sinopharm
 - University of Oxford/AstraZeneca
- Several promising candidates in other Phase trials
- Many more in pre-clinical trials

<https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines>



58

Sinovac

- Inactivated vaccine known as CoronaVac
- 2 dose regime given 14 days apart has induced neutralizing antibodies
- Detailed results not yet available however initial results show a promising safety profile
- Phase 3 trials beginning in Brazil
- ? When it is likely to be ready



59

Beijing & Wuhan Institute of Biological Products/Sinopharm

- Two inactivated vaccines in development
- Not much information available – not yet published
- Claiming high levels of neutralising antibodies following a 2 dose regime.
- One of the vaccines began Phase 3 trials in United Arab Emirates in June
- ? When either is likely to be ready however employees of state owned companies in China are already receiving them.

60

University of Oxford/AstraZeneca

- Non-replicating Viral Vector known as AZD1222
- Contains genetic code of coronavirus protein spikes
- Triggers a strong immune response – both neutralizing antibodies and T-cells
- Recently gone to Phase 3 trials in Brazil and South Africa.
- Possibly ready by late this year if passes trials.

61

Influenza



- Viral illness caused by influenza A or B virus.
- Highest rates in under 5 year olds and 80 years and over.
- Causes significant annual morbidity and mortality in Australians > 50 yrs.
- Total of 310,011 laboratory confirmed cases in Au in 2019.
- Over 800 influenza-associated deaths in 2019 (median age 86 yrs)
- Australia - ~ 0.1% crude case fatality rate (vs. ~1.4% for COVID).

62


Immunisation control strategies

- **Recommended for everyone over 6 months of age**
- Free influenza vaccination for high risk groups:
 - ≥ 6 months to < 5 year olds
 - ≥ 65 years of age
 - Pregnant women at any stage of pregnancy
 - Aboriginal & Torres Strait Islanders
 - Aged ≥ 6 months with high risk conditions
- ≥ 65 year old high dose formulations


63

Influenza notifications

Influenza (A, B, Not specified) notifications in NSW residents, by month of disease onset. January 2016 to March 2020.



<https://www.health.nsw.gov.au/Infectious/Pages/data.aspx>



Health
Northern Sydney
Local Health District

64

No. of +ve influenza laboratory tests NSW

Figure 2: Percent of laboratory tests positive for influenza A and influenza B (combined) reported by NSW sentinel laboratories, 1 January – 5 July 2020 (red line), compared with the 5 previous years




Table 3: Reported influenza outbreaks in NSW institutions, January 2014 to 5 July 2020.

Year	2014	2015	2016	2017	2018	2019	2020*
No. of outbreaks	122	103	252	543	42	383	15

Notes: * Year to date.


Source: Notifiable Conditions Information Management System, accessed 8 July 2020

<https://www.health.nsw.gov.au/Infectious/Influenza/Pages/reports.aspx>

65

No. of influenza laboratory tests NSW

Figure 1: Number of influenza tests conducted at sentinel NSW laboratories per week, 1 January – 5 July 2020 (red line), compared with the 5 previous years



<https://www.health.nsw.gov.au/Infectious/Influenza/Pages/reports.aspx>



Health
Northern Sydney
Local Health District

66

2020 Influenza Vaccines

● Quadrivalent Influenza Vaccines (QIVs):

- an A/**Brisbane**/02/2018 (H1N1)pdm09-like virus
- an A/**South Australia**/34/2019 (H3N2)-like virus
- a B/**Washington**/02/2019-like (B/Victoria lineage) virus
- a B/**Phuket**/3073/2013-like (B/Yamagata lineage) virus



Health
Northern Sydney
Local Health District

67

Timing of vaccination

- Recommended before the onset of influenza season.
- Peak influenza period in Au usually June to September.
- Optimal protection in the first 3 - 4 months but good for the whole season.
- Revaccination in the same season is not recommended, but not contraindicated – only one funded vaccine pp.!
- Never too late to vaccinate - offer as long as influenza is circulating and a valid(unexpired) vaccine is available.

68

ATAGI clinical advice for immunisation providers

Table 1. Seasonal influenza vaccines registered and available for use in Australia in 2020, by age

Vaccine	FluQuadri 0.50 mL (Sanofi)	Vaxigrip Tetra 0.50 mL (Sanofi)	Fluarix Tetra 0.50 mL (GSK)	Afluria Quad 0.50 mL (Seqirus)	Influvac Tetra 0.50 mL (Mylan)	Fluad Quad 0.50 mL (Seqirus)
Registered age group						
6 to 35 months (<3 years)	✓	✓	✓*	x	x	x
≥3 to <5 years	✓	✓	✓*	x	✓	x
≥5 to <65 years	✓*	✓*	✓*	✓*	✓	x
≥65 years	✓	✓	✓	✓	✓	✓†

Ticks indicate age at which a vaccine is registered and available. Shaded boxes represent funding under the NIP.

* Funding only for Aboriginal and Torres Strait Islander people, pregnant women and people who have certain medical conditions.

† Adjuvanted QIV preferred over standard QIVs.

69

Breakdown of influenza vaccines reported to AIR 1 Mar – 15 Jul 2020

	Total	Age			Indigenous		Provider type			Off label*
		<5	5-64 years	65 years+	Yes	No	GP	Pharmacy	Other	
NSW	2,691,351	209,307	1,598,619	883,425	80,664	2,610,687	2,179,950	266,092	245,309	696

2.99 million funded doses delivered as of 6 July

- Over half a million doses not recorded on AIR

70

Schedule FAQs

Parents are taking their 3 month old baby overseas, can you give the 4 month vaccines early?

- Yes but only bring forward in special circumstances i.e. travel, outbreak management.
- Need to be mindful of minimum intervals
- Need to ensure Rotarix age limits are adhered to
- Generally AIR will consider vaccines given earlier than 28 days before they're due as invalid.

71

Calculating a Catch-up plan

The Australian Immunisation Handbook states:

- For incomplete or overdue vaccinations, build on the previous documented dose. Do not start again.
- If more than one vaccine is overdue, 1 dose of each vaccine should be given at the first catch-up visit.
- A catch-up schedule may require multiple vaccinations. **Give all due vaccines at the same visit – do not defer.**

<https://immunisationhandbook.health.gov.au/>



72

Product information vs. Handbook recommendations

- Sometimes ATAGI recommendations in the Handbook may differ from product information.
- These differences may be recommendations that are in addition to or instead of those listed in the PI.
- Variations from the PI are detailed in each relevant disease chapter under the section 'Variations from product information'.
- ***Where a variation exists, the ATAGI recommendation should be considered best practice.***



73

Minimum Dose Intervals for catch-up

- 4 weeks between live vaccines
- 4 weeks between vaccines with the same antigens
- Pneumococcal
 - 1 month between doses if < 12 months of age
 - 2 months if \geq 12 months of age
- Hib
 - 1 month between primary doses
 - 2 months for booster dose

<https://immunisationhandbook.health.gov.au/>

74

Minimum Dose Intervals cont.

- Hepatitis B
 - 4 weeks between dose 1 and 2
 - 8 weeks between dose 2 and 3
 - 16 weeks between dose 1 and 3
- Final primary dose (Dose 3) in infants not before 24 weeks of age
- Monovalent vaccine optimal intervals - 0, 1 and 6 months

<https://immunisationhandbook.health.gov.au/>

75

Acceptable overseas variation for Hepatitis B

- Dose B: Birth dose
+
- Dose 1: 1 – 2 months of age
+
- Dose 2: 6 – 18 months of age

Alternate acceptable adolescent Hepatitis B

- For ages 11 – 15 years
 - X 2 adult formulation monovalent hepatitis B vaccines 4 months apart

<https://immunisationhandbook.health.gov.au/>



76

Vaccine age limits when catching up

- **Birth Hepatitis B** is not caught up past 7 days of age
- **Paediatric Hepatitis B** vaccine up to 19 years of age
- **Adult Hepatitis B** vaccine formulations \geq 20 years of age (apart from 2 dose adolescent regimen)
- **Boostrix and Adacel** formulations - \geq 10 years of age
- **Infanrix and Tripacel** formulations - $<$ 10 years of age
- **Priorix Tetra and Proquad** (MMR and Varicella) - up to the 14th birthday

<https://immunisationhandbook.health.gov.au/>



77

Catch-up tools for children < 10 years of age



78

NSLHD Catch-up education tool

Calculating catch-up vaccination requirements for <10 year olds.

Table 1 sets out the vaccines which are recommended for children under 10 years of age and the doses required for their current age. Use Table 1 in conjunction with Table 2: GP/Practice Nurse catch-up vaccination plan to calculate what vaccines are required.

Table 1: Standard Vaccination Catch-up Recommendations for children aged <10 years.
(adapted from The Australian Immunisation Handbook 10th edition [updated online])

Vaccine	Current age								Minimum dose interval between dose 1 and 2	Minimum dose interval between dose 2 and 3	Minimum dose interval between dose 3 and 4	Minimum dose interval between dose 4 and 5
	6 weeks to <4 months	4 to <6 months	6 to <12 months	12 to 18 months	>18 months to <4 years		4 years to <10 years					
					Born before 1 Oct 2014	Born after 1 Oct 2014	Born before 1 Oct 2014	Born after 1 Oct 2014				
	Doses required											
DTPa	1	2	3	3	3	4	4 ²	5	4 weeks	4 weeks	6 months	6 months
Poliomyelitis (IPV)	1	2	3	3	3	3	4 ³	4 ³	4 weeks	4 weeks	4 weeks	Not required
Hepatitis B ⁴ (excl. birth dose)	1	2	3	3	3	3	3	3	1 month ⁵	2 - 3 months ⁵	Not required	Not required
MMR ⁶	if given at <11 months of age the 1 st dose should be repeated at 12 months of age.			1	2	2	2	2	4 weeks	Not required	Not required	Not required
MenCCV/4vMenCV	if given at <11 months of age a booster dose is required at 12 months of age or 8 weeks after last dose, whichever is later.			1	1	1	1	1	Not required	Not required	Not required	Not required
Varicella ⁵	if given at <12 months of age, the dose should be repeated, preferably at 18 months of age.			1	1	1	1	1	Not required	Not required	Not required	Not required
Rotavirus	Age limits apply - see Handbook Table 4.17.1		NO CATCH-UP									
Haemophilus influenzae type B (Hib) - No catch-up > 5 years.	See Handbook Table 2.1.8 for Hib catch-up schedule ⁷								Recommended interval between primary doses is 4 weeks. Booster doses are given >12 months or 8 weeks after the last dose, whichever is later.			
Pneumococcal (PCV) - No catch-up > 5 years for healthy kids.	See Handbook Table 2.1.9 & 2.1.11 for PCV catch-up schedule ⁷								Recommended interval between doses is 4 weeks if aged <12 months and 8 weeks if ≥12 months.			

¹ All children born after 1 October 2014 are required to have had an 18 months booster dose of DTPa vaccine.

² Some children may have received 4 doses of DTPa by 18 months of age, especially if arrived from overseas. These children will require a 5th dose of DTPa after 4 years of age.

³ A booster dose of IPV is recommended at 4 years of age. If the 4th dose was given before 3.5 years of age, it should be repeated. If 3rd dose of IPV is given after 4 years of age, a 4th dose is *not required*.

⁴ Acceptable alternate overseas schedule: Monovalent Hep B vaccine at birth, 1-2 months and 6-18 months of age if given overseas.

⁵ MINIMUM interval between dose 1 and 3, is 4 months. MINIMUM interval between dose 2 and 3 is 2 months (however, the optimum schedule is 0, 1 & 6 months). The MINIMUM age for dose 3 is 24 weeks.

⁶ MMRV is not recommended for use as the 1st dose of MMR containing vaccine in children aged <4yrs. **ANY live vaccines can be given on the same day, if not there must be a minimum interval of 4 weeks.**

⁷ Required doses vary depending on age at presentation and age when vaccine received; therefore tables *must* be referred to for each new catch-up.

Updated September 2018

<https://www.nslhd.health.nsw.gov.au/HealthInformation/PublicHealthUnit/Pages/Immunisation.aspx>

79

Catch-up Worksheet

Table 2: GP/Practice Nurse catch-up vaccination plan

Instructions: Use this form in conjunction with Table 1. Complete all sections below, working from left to right columns.

If you would like your calculations checked either fax or email this form to:
 Fax: 9482 1650 Email: NSLHD-PHUHornsby@health.nsw.gov.au

Practice Name: _____
 Contact Person: _____
 Ph: _____ Fax: _____

PATIENT'S NAME: _____ DOB: ___/___/___ Current age: ___ (years) ___ (months) ___ (weeks) MEDICARE NO: _____

Vaccine Antigens	Date(s) all doses given (complete all relevant dates)	Age when dose was given**	No. doses given (circle one)		No. further doses required (circle one)		Australian NIP vaccine formulations for catch-up in children <10 years of age	CATCH-UP PLAN Check minimum dose intervals between each dose as per Table 1.
			No. VALID**	No. doses required at current age (see Table 1)	No. further doses required (circle one)			
Diphtheria Tetanus Pertussis (DT only vaccines are not valid for the purposes of determining catch-up)			None One Two Three Four Five	One Two Three Four Five	None One Two Three Four Five	None One Two Three Four Five	Choose the vaccine with the least amount of additional antigens. DTPa containing vaccines • Infanrix Hexa (DTPa + Polio + Hib + HepB) • Infanrix/Tripacel (DTPa only) • Infanrix IPV (DTPa + Polio) • Quadracel (DTPa + Polio) NB: Boostrix and Adacel brands are not registered for use ≤10 yrs of age.	Give all the vaccines that are due now – do not defer. Visit 1 give now:
Poliomyelitis (IPV or OPV) Booster dose recommended at 4 years of age. If the 4 th dose was given before 3.5 years of age, it should be repeated.			None One Two Three Four Five	One Two Three Four	None One Two Three Four	None One Two Three Four		Visit 2 (Min ___ months later) give:
Hepatitis B Administered overseas?: yes / no	Birth: _____	N/A	(<i>excl. birth dose</i>) None One Two Three	One Two Three	None One Two Three	None One Two Three	MMR combination vaccines • MMRII or Priorix (MMR only) • Priorix Tetra or Proquad (MMRV) – not for dose 1 MMR NB: MMRV brands are not registered for use ≥14 yrs of age.	Visit 3 (Min ___ months later) give:
MMR (NOT including measles only vaccine)			None One Two	None One Two	None One Two	None One Two	Meningococcal vaccines • Nimenrix* (4cMenCV) • Menitorx (MenCCV+Hib) – for Hib catch-up only if Act-HIB unavailable NB: * This is the only funded 4cMenCV for catch-up in <10 yrs of age.	Visit 4 (Min ___ months later) give:
Meningococcal C (MenCCV/4vMenCV) <small>Scitrigate only. Polysaccharide (vMnMenPV) vaccine is not counted as a valid dose.</small>			None One Two Three	None One Two	None One Two	None One Two		
Varicella			None One Two	None One	None One	None One	Monovalent vaccines • Engerix-B or H-B-VaxII paediatric formulations (Hep B only) • Varivax or Varivax (varicella only) • POL (Polio only) • Prevenar 13 (PCV only) • Act-HIB (Hib only)	
Haemophilus influenzae (Hib) (Only required if < 5 years old)			None One Two Three Four	See Handbook Table 2.1.8	None One Two Three	None One Two Three		
Pneumococcal (PCV) (Only required if < 5 years old – unless underlying medical risks)			None One Two Three Four	See Handbook Table 2.1.9 and 2.1.11	None One Two Three	None One Two Three		

* Monovalent Hep B vaccine at birth, 1-2 months and 6-18 months of age is an acceptable alternative overseas Hep B schedule.
 **Ensure minimum intervals have been observed as per Table 1.

Updated September 2018
 OFFICE USE ONLY: Checked by _____ (NSPHU Immunisation Team) Date: ___/___/___
<https://www.nslhd.health.nsw.gov.au/HealthInformation/PublicHealthUnit/Pages/Immunisation.aspx>

80


Australian Immunisation Handbook Catch-up Calculator

- First release of the [National Immunisation Catch-up Calculator \(NICC\)](#)
- Only for < 10 years of age in this version
- Developed by the Australian Government Department of Health
- Available from the Australian Government Department of Health Australian Immunisation Handbook website.
- Replaces the immunisation calculator hosted on the South Australian Department of Health website.



<https://immunisationhandbook.health.gov.au/catch-up-calculator/calculator>

81



Australian
Immunisation
Handbook

Version 1.02 (11 February 2020)

Catch-up schedule

Note: If the person does not present on the date/s recommended in this catch-up schedule, a new calculation should be undertaken at each visit to ensure that minimum intervals between antigen doses are met and the recommended schedule remains current.

This is a catch-up schedule. Once the person has caught up, they may need more recommended NIP vaccines in the future.

John Doe
Date of birth: 16/07/2018
Gender: Male
Aboriginal or Torres Strait Islander: No
Immunisation record(s) viewed: Birth record
Prescription immunosuppressive medication: No
State: NSW
Date created: 29 July 2020
Age: 2 years, 13 days

Vaccination history

Person has not received any immunisations to date.

Vaccinations due

Due immediately

29 July 2020
Diphtheria, Tetanus, Pertussis
Hepatitis B
Haemophilus Influenzae Type B
Meningococcal ACWY
Measles, Mumps, Rubella
Pneumococcal
Polio

Next appointment

26 August 2020
Diphtheria, Tetanus, Pertussis
Hepatitis B
Measles, Mumps, Rubella
Polio
Varicella

Future appointment(s)

23 September 2020
Diphtheria, Tetanus, Pertussis
Polio

18 November 2020
Hepatitis B

23 March 2021
Diphtheria, Tetanus, Pertussis

16 July 2022
Diphtheria, Tetanus, Pertussis
Polio

(Page 1 of 2)

(Page 2 of 2)

82

Catch-up tools for people over 10 years of age



83

Table 1: Nationally funded catch-up vaccines for children aged 10–19 years

Antigen	Total doses needed	Minimal interval between doses	Notes
Diphtheria, tetanus	3 doses	Between doses 1 and 2: 4 weeks Between doses 2 and 3: 4 weeks	People should receive 1 of the doses as dTpa containing vaccine and complete the course with dT. This dose would also provide the catch-up dose for pertussis. If dT is not available, use dTpa or dTpa-IPV for all 3 primary doses.
Pertussis	1 dose	Not required	People >10 years of age who did not receive all the pertussis vaccine doses recommended before the age of 10 years only need 1 dose to be considered up to date. This is regardless of the number of previous doses they received before the age of 10 years. A booster dose of pertussis-containing vaccine is routinely recommended for all adolescents aged 11–13 years. Take this into account when planning catch-up for pertussis.
Poliomyelitis	3 doses	Between doses 1 and 2: 4 weeks Between doses 2 and 3: 4 weeks	None
Measles, mumps and rubella	2 doses	4 weeks	None
Hepatitis B	3 paediatric doses aged 10–19 years 2 adult doses aged 11–19 years only	Between doses 1 and 2: 1 month Between doses 2 and 3: 2 months	Minimum interval between dose 1 & 2
		4 months	None
			Meningococcal
			1 dose of meningococcal C vaccine aged 10–14 years
			Not required
			None
			1 dose of meningococcal ACWY vaccine aged 15–19 years
			Not required
			None
			Varicella
			At least 1 dose if aged <14 years
			Between doses 1 and 2: 4 weeks (if 2nd dose is given)
			Recommended for all non-immune people. People aged <14 years are recommended to receive at least 1 and preferably 2 doses (only one dose is funded). Children aged under 14 years can receive MMRV.
			2 doses if aged >14 years
			4 weeks
			2 doses are recommended for all non-immune people aged >14 years. MMRV is not recommended for use in people >14 years of age.
			Human papillomavirus
			2 doses if started at 9–14 years of age
			6 months
			If there is an interval of <5 months between doses 1 and 2, a 3rd dose is needed at least 12 weeks after the 2nd dose. (Note only two doses are funded). If there is an interval of <6 months but >5 months between doses 1 and 2, a 3rd dose is not needed. People who are immunocompromised need a 3-dose schedule, regardless of age when they start vaccination.
			3 doses if started at >15 years of age
			Between doses 1 and 2: 4 weeks Between doses 2 and 3: 12 weeks
			Minimum interval between dose 1 and dose 3 is 5 months. (Note only two doses are funded).

<https://www.health.gov.au/resources/publications/free-catch-up-vaccines-for-10-to-19-year-olds-fact-sheet>

84

Table 1: Nationally funded catch-up vaccines for refugees and other humanitarian entrants aged 20 years and over

Antigen	Total doses needed	Minimal interval between doses	Notes
Diphtheria, tetanus	3 doses	Between doses 1 and 2: 4 weeks Between doses 2 and 3: 4 weeks	People should receive 1 of the doses as dTpa-containing vaccine to provide the catch-up dose for pertussis. The course can be completed with dT. If dT is not available, use dTpa or dTpa-IPV for all 3 primary doses.
Pertussis	1 dose	Not required	People >10 years of age who did not receive all the pertussis vaccine doses recommended before the age of 10 years only need 1 dose to be considered up to date. This is regardless of the number of previous doses they received before the age of 10 years.
Poliomyelitis	3 doses	Between doses 1 and 2: 4 weeks Between doses 2 and 3: 4 weeks	None
Measles, mumps and rubella	2 doses	4 weeks	None
Hepatitis B Aged >20 years	3 adult doses	Between doses 1 and 2: 1 month Between doses 2 and 3: 2 months	Minimum interval between dose 1 and dose 3 is 4 months.
Varicella	2 doses	4 weeks	MMRV is not recommended for use in people >14 years of age.

<https://www.health.gov.au/resources/publications/free-catch-up-vaccines-for-refugees-and-humanitarian-entrants-aged-20-years-and-over-fact-sheet>

85

NSPHU Catch-up recommendation info.

Standard Vaccination Catch-up Recommendations for people over 10 years of age (adapted from the Australian Immunisation Handbook (available online)).

Antigen	Doses required	Min. interval b/w dose 1 and 2	Min. interval b/w dose 2 and 3	Notes	
Diphtheria, tetanus, pertussis (dTpa)	3 doses	4 weeks	4 weeks	One dose should be given as dTpa (or dTpa-IPV if polio is also needed) and the course completed with dT. If dT is not available, use dTpa or dTpa-IPV for all 3 primary doses. A booster dose of dTpa is offered in Year 7. Take this into account when planning catch-up for pertussis.	
Poliomyelitis (IPV)	3 doses	4 weeks	4 weeks	None.	
Hepatitis B	10-19 years [^]	3 paediatric doses	1 month	2 – 3* months	[^] The age groups overlap and this is an either/or, not both. [*] MINIMUM interval b/w dose 1 & 3 is 4 months (however, optimum schedule is 0, 1 & 6 months). [†] This is not funded, unless the patient falls into the risk group for a funded vaccine (refer to: https://www.health.nsw.gov.au/immunisation/Pages/gp_catchup.aspx).
	11-15 years [^]	2 adult doses	4 months	Not required	
	≥20 years [†]	3 adult doses	1 month	2 – 3* months	
Measles, mumps, rubella (MMR)	2 doses	4 weeks	Not required	MMR vaccines are free for everyone in NSW born during or after 1966 or for vaccination of rubella seronegative post natal women.	
MenCCV/ 4vMenCV	10-14 years	1 dose of men C	Not required	Not required	Recommendations are for healthy individuals. Refer to the Australian Immunisation Handbook for recommendations for people with medical conditions that increase their risk of invasive meningococcal disease (Vaccines are not funded).
	15-19 years	1 dose of men ACWY	Not required	Not required	
Varicella	<14 years	1 dose	Not required	Not required	People aged <14 years should preferably receive 2 doses (only one dose is funded).
	≥14 years	2 doses	4 weeks	Not required	People aged ≥14 years are recommended to receive 2 doses (two doses are funded from 14-19 years of age). MMRV is not recommended for use in people ≥14 years of age.
Human papillomavirus (HPV)	9-14 years	2 doses	6 months [*]	Not required	[*] If there is an interval of <5 months between doses 1 and 2, a 3rd dose is needed at least 12 weeks after the 2nd dose. (Only two doses are funded).
	≥15 years	3 doses	4 weeks	12 - 16 [†] weeks	[†] MINIMUM interval b/w dose 1 and dose 3 is 5 months. (Only two doses are funded). Immunocompromised people need a 3-dose schedule, regardless of age. HPV vaccination is funded in NSW for refugees (females and males) 20-26 years of age. HPV vaccination is not registered for men ≥27 years of age and women ≥46 years of age.

<https://www.nslhd.health.nsw.gov.au/HealthInformation/PublicHealthUnit/Pages/Immunisation.aspx>

86

Schedule FAQs

Can I bring the 18 month vaccines forward?

- MMRV can be given early, in special circumstances.
- Hib and DTPa are booster doses and should not be bought forward.



87

Adolescents



2020 High School Program

- Year 7
 - dTpa
 - HPV x 2 doses (6 month interval)
- Year 8 – Catch-up HPV
- Year 10 – Men ACWY
- Intensive English Centers as above +
 - Polio
 - MMR
 - HBV
 - Varicella



88

HPV recommendations

- Gardasil 9 – 9vHPV
- Age at commencement of course:
 - 11 – 14 years: 2 doses, 6 months apart (ideally within 12 months).
 - ≥ 15 years: 3 doses @ 0, 2 and 6 months.
- Immunocompromised: 3 doses @ 0, 2 and 6 months (funded)
- 2 doses are funded for non-immunocompromised, 3rd dose otherwise on script



89

High school vaccination records

Vaccines offered in the school program since 2003 - no records are available prior to 2003.

Human Papillomavirus vaccine offered to: <ul style="list-style-type: none"> Female students in Years 10, 11 & 12 in 2007 Female students in Years 7, 8, 9 & 10 in 2008 All female students in Year 7 from 2009 	<ul style="list-style-type: none"> Male students in Year 9 in 2013 and 2014 All male students in Year 7 from 2013 All Year 7 students from 2013
Diphtheria/Tetanus/Pertussis vaccine offered to: <ul style="list-style-type: none"> all high school students in 2004 all Year 10 students from 2009 - 2012 all Year 7 students in 2005 & from 2010 	Meningococcal ACWY vaccine offered to: <ul style="list-style-type: none"> Year 11 & 12 students in 2017 Year 10 & 11 students in 2018 all Year 10 students from 2019
Hepatitis B vaccine offered to: <ul style="list-style-type: none"> all Year 7 students only 2004 - 2013 	Chickenpox (Varicella) vaccine offered to: <ul style="list-style-type: none"> all Year 7 students only 2006 - 2017
Measles/Mumps/Rubella vaccine offered to: <ul style="list-style-type: none"> Year 9 & 10 in some schools in 2014 Year 11 & 12 students in 2015 	Meningococcal C vaccine offered to: <ul style="list-style-type: none"> all High School students in 2003 & 2004 all Primary School students in 2004

To access high school records:

- Now uploaded to AIR within a week of receipt of vaccination.
- Includes historical records dating back to 2004.
- Providers and individuals access records directly from AIR.




Health
Northern Sydney
Local Health District

90

Vaccination of pregnant women

Maternal pertussis vaccination

- Recommended at 20 – 32 weeks (ideally 28 weeks) each pregnancy, including those that are closely spaced.
- If the vaccine has not been given by 32 weeks gestation, give any time up to delivery.
- If vaccination does not occur prior to delivery, antenatal administration is recommended.



Health
Northern Sydney
Local Health District

91

Why we do antenatal pertussis vaccination

- Direct passive protection of the newborn by transplacental transfer of high levels of pertussis antibodies.
- High levels of maternal antibodies give temporary protection to the baby until they complete their vaccinations.
- Reduces significant pertussis associated morbidity in infants, particularly < 3 months of age.
- Less effective at preventing mild disease.



https://www.researchgate.net/publication/323476368_Effectiveness_of_maternal_pertussis_vaccination_in_preventing_infection_and_disease_in_infants_The_NSW_Public_Health_Network_case-control_study

92

How successful has it been?

- More effective in reducing the risk of pertussis in young infants than any previous strategies.
- Prior to the introduction in NSW ~ 1 death/year in infants aged < 2 months.
- Since the introduction of the vaccine in 2015:
 - ✓ there has been a decrease in cases in children < 6 months (> 200 in 2015, compared to < 100 in 2018).
 - ✓ there have been no deaths in infants in NSW.



<https://www.health.nsw.gov.au/Infectious/Reports/Publications/cdwr/2019/cdwr-week10-2019.pdf>

93

Influenza in pregnancy



- Can be life threatening for pregnant women and their baby.
- Changes in immune, heart and lung functions increases the likelihood of severe illness.
- At a higher risk of hospitalisation and death.
- Severe influenza illness increases the chance of premature birth and low birth weight.

Why we do antenatal influenza vaccination

- Protects the mother against influenza and complications resulting from it.
- Protects newborns and babies aged < 6 months - more likely to be hospitalised with influenza than any other age group.
- Estimated to reduce the risk of influenza in this age group by approximately 50%.

Vaccination timing

- Give any time during pregnancy (as early as possible).
- Best given before the onset of the flu season (usually begins in April and peaks August).
- Optimal timing mid-April onwards
- Protection expected to last for the season (optimal in the first 3 – 4 months following vaccination)
- Can be given twice during pregnancy if spanning two seasons.
- Can be given at the same time as the antenatal pertussis vaccine (but don't wait).



<https://immunisationhandbook.health.gov.au/vaccine-preventable-diseases/pertussis-whooping-cough>

96

Schedule FAQs

Can you still give 4 years immunisation as early as 3.5 years?

No.

- Changed since the introduction of the 18 month booster dose in 2016.
- Now recommended at 4 years of age only.



97

Adults



HALO Principle

H Health – medical condition/s that may put them at risk


A Age – older people at higher risk of certain diseases, targeting of groups

L Lifestyle – travel, aged care etc

O Occupation – type of employment



98

 National Centre for Immunisation Research and Surveillance

Immunisation recommendations for Non-Indigenous Australians without risk factors for vaccine-preventable diseases

This table is a summary of vaccine recommendations from the [Australian Immunisation Handbook](#) for non-Indigenous Australians based on age and pregnancy status. Shaded cells represent vaccinations funded under the National Immunisation Program (NIP).^a Brackets indicate that these vaccines are only recommended for a population sub-group. More detail is provided in the corresponding footnote(s).

Disease/vaccine antigen	Abbrev.	Age										Pregnancy status				
		At birth	2 months ^b	4 months	6 months	12 months	18 months	4 years	Adolescents	Adults	During pregnancy	Post-partum				
Hepatitis B	HepB	✓	✓ ^a	✓ ^a	✓ ^a	✓ ^a	(✓) ^c									
Diphtheria, tetanus, pertussis	DTPa/dTpa		✓ ^a	✓ ^a	✓ ^a			✓	✓ ¹	✓ 12–13 years ^d	✓ 65 years ^e	✓ ^a	(✓) ^a			
Poliomyelitis	IPV		✓ ^a	✓ ^a	✓ ^a				✓ ¹							
Haemophilus influenzae type b	Hib		✓ ^a	✓ ^a	✓ ^a			✓								
Pneumococcal	13vPCV		✓	✓	check for medical risk conditions	✓					✓ 270 years					
	23vPPV							Check for medical risk conditions								
Rotavirus			✓	✓												
Measles, mumps, rubella	MMR					✓	✓ ^{1, f}					(✓) ^g	(✓) ^g			
Varicella	VV						✓ ²		✓ ^h			(✓) ^g				
Meningococcal serogroup B	MenB				✓			(refer to footnote i)	✓ 15–19 years ⁱ			(refer to footnote i)				
Meningococcal serogroup ACWY	MenACWY			✓ ⁱ		✓		(refer to footnote i)	✓ 15–19 years; NIP school program doses at 14–16 years ^j			(refer to footnote i)				
Influenza (annual)	QIV					✓ ^k			(refer to footnote k)	✓ 265 years ^k		✓				
Human papillomavirus	HPV								✓ 12–13 years ^l							
Herpes zoster	HZ										✓ 270 years ^m					

http://ncirs.org.au/sites/default/files/2020-06/NCIRS%20Immunisation%20schedule%20for%20non-Indigenous%20people_1%20July%202020_Final.pdf

Last updated 1 July 2020


99

People with Occupational Risk



100

Policy Directive



Occupational Assessment, Screening and Vaccination Against Specified Infectious Diseases

Summary Framework for the assessment, screening and vaccination of healthcare worker, students and other personnel to minimise the risk of transmission of diseases.

Document type Policy Directive

Document number PD2020_017

Publication date 27 May 2020

Author branch Health Protection NSW

Branch contact (02) 9391 9195

Replaces PD2020_016

Review date 27 May 2025

Policy manual Not applicable

File number H20/55149

Status Active

Functional group Personnel/Workforce - Employment Screening, Occupational Health and Safety
Population Health - Communicable Diseases, Health Promotion, Infection Control


Applies to Ministry of Health, Public Health Units, Local Health Districts, Board Governed Statutory Health Corporations, Chief Executive Governed Statutory Health Corporations, Speciality Network Governed Statutory Health Corporations, Affiliated Health Organisations, NSW Health Pathology, Public Health System Support Division, Cancer Institute, Government Medical Officers, Community Health Centres, NSW Ambulance Service, Dental Schools and Clinics, Public Hospitals

Distributed to Ministry of Health, Public Health System, Government Medical Officers, NSW Ambulance Service

Audience All Clinical Staff

Healthcare worker vaccination

- Diphtheria, Tetanus & Pertussis
- Hepatitis B
- Measles, Mumps & Rubella
- Varicella
- Influenza
- Tuberculosis

 **Health**
Northern Sydney
Local Health District

https://www1.health.nsw.gov.au/pds/ActivePDSDocuments/PD2020_017.pdf

101

Revisions

2018

- New Category A High Risk included
- Mandatory influenza vaccination for Category A High Risk
- Recommendations for termination of staff who refuse to comply
- Hepatitis B vaccination statutory declaration

2020

- Removed the requirement that students are assessed for TB compliance within 4 months of their first clinical placement
- Mandatory influenza vaccination requirements for workers in Multi-Purpose Services and State Government ACF
- Enhanced TB control measures introduced
- Inclusion of additional documents that can be used to demonstrate compliance



https://www1.health.nsw.gov.au/pds/ActivePDSDocuments/PD2020_017.pdf

102

Occupational Assessment Screening and Vaccination Against Specified Infectious Diseases APPENDICES



Appendix 4 Checklist: Evidence required from Category A Applicants

Workers, new recruits, other clinical personnel and students should take this checklist (and relevant sections of this policy directive referred to in this checklist) to their immunisation provider and discuss their screening and vaccination requirements.

Acceptable evidence of protection includes a written record of vaccination signed, dated and stamped by the medical practitioner/nurse immuniser on the NSW Health vaccination record card for health care workers and students and/or serological confirmation of protection, and/or other evidence, as specified in this table. An air transcript is also acceptable evidence of vaccination.

Diseases	Vaccination Evidence	Serology Evidence	Other Acceptable Evidence	Comments
Diphtheria, Tetanus & Pertussis	One adult dose of dTpa vaccine within the last 10 years	N/A. Serology will <u>not</u> be accepted	NIL	<ul style="list-style-type: none"> • dTpa booster is required 10-yearly • DO NOT use ADT vaccine
Hepatitis B	History of age-appropriate hepatitis B vaccination course	AND Anti-HBs \geq 10mIU/mL	OR Documented evidence of anti-HBc, indicating past hepatitis B infection, or HBsAg+	<ul style="list-style-type: none"> • A completed <i>Hepatitis B Vaccination Declaration</i> (Appendix 9) are acceptable if all attempts fail to obtain the vaccination record. The assessor must be satisfied that a reliable history has been provided and the risks of providing a false declaration or providing a verbal vaccination history based on recall must be explained • Positive HBcAb and/or HBsAg result indicate compliance with this policy • A further specialist assessment is required for HBsAg+ workers who perform Exposure Prone Procedures
Measles, Mumps & Rubella (MMR)	2 doses of MMR vaccine at least one month apart	OR Positive IgG for measles, mumps and rubella (Rubella immunity is provided as a numerical value with immunity status as per lab report)	OR Birth date before 1966	<ul style="list-style-type: none"> • Two doses of MMR vaccine, given at least 4 weeks apart, should be accepted as compliance with this policy. • Do <u>not</u> compare the numeric levels reported from different laboratories. The interpretation of the result given in the laboratory's report must be

PD2020_017


Issue date: May-2020

Page 36 of 45

https://www1.health.nsw.gov.au/pds/ActivePDSDocuments/PD2020_017.pdf


103

				<p>followed i.e. the report may include additional clinical advice e.g. consideration of a booster vaccination for low levels of rubella IgG detected.</p> <ul style="list-style-type: none"> DO NOT use MMRV vaccine (not licensed for use in persons \geq 14 years). If a dose of MMRV vaccine is inadvertently given to an older person, this dose does not need to be repeated Serology is <u>not</u> required following completion of a documented two dose MMR course. Those born before 1966 do <u>not</u> require serology
Varicella	2 doses of varicella vaccine at least one month apart (or evidence of 1 dose if the person was vaccinated before 14 years of age).	OR Positive IgG for varicella	Australian Immunisation Register (AIR) History Statement that records natural immunity to chickenpox	<ul style="list-style-type: none"> Evidence of one dose of varicella vaccine is sufficient in persons vaccinated before 14 years of age; two doses administered at least one month apart is required when aged 14 years or more when vaccinated. DO NOT use MMRV vaccine (not licensed for use in persons \geq 14 years) Evidence of one dose of Zostavax in persons vaccinated over 50 years of age
Influenza	One dose of current southern hemisphere seasonal influenza vaccine by 1 June each year	N/A Serology will not be accepted	NIL	<ul style="list-style-type: none"> Influenza vaccination is required annually for workers in Category A High Risk positions, as specified in Appendix 1 <i>Risk Categorisation Guidelines</i> (see Section 4) Influenza vaccination is strongly recommended for all workers, other clinical personnel in Category A positions and for all students.
Tuberculosis	N/A	Refer to Section 3.5	Refer to Section 3.5	<ul style="list-style-type: none"> Refer to Section 1.2 <i>Key Definitions</i> Refer to Section 3 <i>TB Assessment and Screening</i>



Australian Immunisation Handbook App.

- Australian Immunisation Handbook (AIH) is now available as a mobile application.
- All content is accessible on most mobile devices, such as smart phones or tablets.
- Enables access to the AIH content - even when you do not have access to the Internet.



<https://immunisationhandbook.health.gov.au/about-the-handbook/mobile-app>

106

Sharing Knowledge About Immunisation (SKAI) - eLearning module

- 90 minute learning module for healthcare professionals
- Assists with avoiding extended or confrontational interactions.
- Provides information to help address parents' questions or concerns.
- Recommendation for structuring vaccination consultations.
- Tips from experienced clinicians.



<http://www.ncirs.org.au/health-professionals/skai-supporting-health-professionals>

107

Vaccine Supply by Pharmacists in NSW

- In NSW appropriately trained pharmacists are authorised to supply and administer without a prescription:
 - Privately funded MMR, dTpa from 16 years of age
 - Privately funded influenza vaccines from 10 years of age
- Federal government has agreed to expand this authority to allow access to NIP funded vaccines - pending State and Territory approval
- Want access to all NIP vaccines with the exception of early childhood vaccines



108

NCIRS report – Review of pharmacist vaccination

- [“Review of pharmacist vaccination reporting to the Australian Immunisation Register”](#) - released May 2020.
- Influenza vaccine the most commonly administered vaccine.
- Greatest uptake of pharmacist vaccination in regional areas and in 50–64 years.
- Highlights the expanding role of pharmacists in providing vaccinations.
- Identifies gaps in reporting to the Australian Immunisation Register (AIR).
- Of the over 2 million influenza vaccinations reportedly given by pharmacists in 2019, only a quarter were recorded on AIR.

109



110

Recommended sites for childhood vaccinations in NSW

JULY 2020 SCHEDULE

6 MONTHS AND 18 MONTHS

- Rotarix® (RV)** (Oral) - Rotavirus (Oral only)
- Infanrix Hexa® (IH)**
- Prevnar 13® (IPV)**
- Infanrix® (IM)**

8 MONTHS

- Annual Influenza funded for:**
 - All children 6 months to less than 5 years of age.
 - All Aboriginal people 6 months.
 - All people 65 months with a risk medical.
- At risk children 6 months** requires an additional dose of Prevnar 13® (immunisation only refer to AHP online).
- Aboriginal children 6 months** with certain medical conditions may require an additional dose of Meningococcal B - refer to AHP online.
- Infanrix Hexa® (IH)**

12 MONTHS

- Rotarix® (RV)** (Oral) - Rotavirus (Oral only)
- Prevnar 13® (IPV)**
- Infanrix Hexa® (IH)**
- MMW B (IM or SC) or Trimer® (IM or SC)**
- Additional dose of Hepatitis B vaccine recommended at 12 months for low birth weight (2000gms) and/or infants born at 132 weeks gestation - refer to AHP online.**

18 MONTHS

- Ac-Hib® (IM)**
- Infanrix® (IM) or Trimer® (IM)**
- Prevnar 13® (IPV or SC)**
- Thimote® (IM or SC)**

4 YEARS

- At risk children** require a dose of Prevnar 13® (immunisation only) at 12 months after Prevnar 13® or age 4 years whichever is first.
- Infanrix® (IM) or Trimer® (IM)**

INTRAMUSCULAR (IM)
90° to skin plane

SUBCUTANEOUS (SC)
45° to skin plane

ADMINISTERING 3-4 VACCINES AT ONE VISIT

- Ensure 2.5cm between injections in the same muscle.
- If the child is receiving 3 or 4 vaccines at 12 months or earlier and dilated muscles mass is inadequate.

Before Vaccination:

- Adminise 45 minutes available.
- Ensure vaccine cold chain maintained.
- The vaccination site site attended.
- Identify all medical at risk children and Aboriginal children - requiring additional vaccines as per AHP online.
- Check child's immunisation history or IM.
- Informed consent obtained and documented.
- Check if the vaccine needs to be discontinued.
- Ensure correct vaccine for age and give all scheduled vaccines in one visit if possible.

Post Vaccination:

- Child remains in clinic for 15 minutes.
- Provide parents/care with Handout - What to Expect & What to do!
- Add small reminder for next visit.

Booster®

- Children >2 years of age are recommended to receive meningococcal polysaccharide (M) (immunisation only) or as soon as practical after Prevnar® vaccination.
- Adults parents/care to follow up with 1 hour dose of penicillin 100mg 4 times daily, regardless of whether the child has a fever.
- Children >2 years of age can receive booster if received separately from other infant vaccines, with a minimum interval of 3 days.

At Risk Groups

- Minor Meningococcal polysaccharide (M) vaccine are funded for all people with:
 - Asplenia
 - Hypoplasia
 - Complete deficiency
 - Treatment with Splenectomy
- Refer to AHP online.

https://static1.squarespace.com/static/5b04e035f93fd49e35a6ba32/t/5f151f95e2fd42124c01a019/1595219865185/ImmunisationPosterA3_14+JULY.pdf

111

Australia's trusted independent immunisation experts


NCIRS National Centre for Immunisation Research and Surveillance

Join our team Publications Reports Contact Search...

For health professionals For the public Our work News & events About us

NCIRS factsheets, FAQs and other resources

Access these resources here



- Fact sheets and FAQs
- Latest vaccine safety data
- Latest reports
- History of immunisation

News & events [All news & events >](#)

26 April 2020 | News 23 July 2020 | News

<http://www.ncirs.org.au/>

112

NCIRS specialist immunisation services resources

New South Wales

Advice line	<p>Health professionals are encouraged to contact their local PHU as their first point of contact.</p> <p>Tel: 1300 066 055</p> <p>Further support:</p> <p>NSW Immunisation Specialist Service (NSWISS)</p> <p>Tel: 1800 NSWISS (1800 679 477)</p> <p>9 am - 5 pm (Mon-Fri)</p>
Clinics	<p>The Children's Hospital at Westmead:</p> <ul style="list-style-type: none"> Specialist Immunisation Clinic Telehealth consultations 1800 679 477 <p>Sydney Children's Hospital Randwick:</p> <ul style="list-style-type: none"> Specialist Immunisation Clinic - (02) 9382 1470 <p>John Hunter Hospital</p> <ul style="list-style-type: none"> Children's Specialist Clinics (Paediatric Immunologist accepts referrals) - (02) 4921 3670
Adverse events reporting	<p>A suspected AEFI in NSW should be reported by contacting your local Public Health Unit (PHU). Your PHU will complete the National Adverse Events Following Immunisation (AEFI) Reporting Form and forward it to the NSW Health Immunisation Unit for forwarding to the Therapeutic Goods Administration (TGA).</p> <p>Tel: 1300 066 055</p>

<http://www.ncirs.org.au/health-professionals/specialist-immunisation-services>

113

Australian Government
Department of Health

Australian Immunisation Handbook

About the Handbook Contact us

Enter your search term

Home Contents Diseases Vaccines Catch-up vaccination Resources

The Australian Immunisation Handbook provides clinical advice for health professionals on the safest and most effective use of vaccines in their practice.

These recommendations are developed by the [Australian Technical Advisory Group on Immunisation](#) (ATAGI) and approved by the [National Health and Medical Research Council](#) (NHMRC).

[About the Handbook](#) →

Handbook quicklinks

- Vaccine preventable diseases
- Vaccination for special risk groups
- Catch-up vaccination
- National Immunisation Catch-up Calculator

<https://immunisationhandbook.health.gov.au>

114

Australian College of Nursing
'Immunisation for Health Practitioners'

Mode of delivery: Distance education – on line with tutor support

Workload/CPD hrs: Self placed - equivalent to 120 hrs CPD

CPD subject fee: \$970 (non members) \$873 (members)

CPD enrolment: Monthly

Pre-requisites:

1. Hold a qualification leading to registration recognised by the relevant National Board
2. General registration as a nurse, midwife, paramedic, pharmacist with the relevant National Board

➤ Successful completion of this course is a requirement for authorisation to administer vaccination without the direction of a medical officer within NSW.

NSW GOVERNMENT | **Health Northern Sydney Local Health District**

<https://www.acn.edu.au/education/immunisation/immunisation-for-health-practitioners>

115

Qld Health Online Immunisation Courses

Immunisation Course 1: Vaccine administration IC-V

ONLINE



Register

Duration
9 hours

Certificate
Provided upon completion

Price (excludes GST)
Everyone \$0.00

Course description

This online course provides a comprehensive overview of the complex and ever changing topic of immunisation for those who receipt, administer or manage vaccines in Queensland.

You will learn what vaccines are made of and how they work in the immune system, how to prepare and administer vaccines, and how to care for patients post vaccination. The course also explains the National Immunisation Program schedule, the vaccination requirements for special groups and equips you with knowledge to respond to vaccine hesitancy.

This course is for general education purposes only and does not lead to authorisation as an Immunisation Program Nurse.

If you experience any technical issues with the course, please read the FAQ's first here. If this does not resolve your issue, contact immunisation@health.qld.gov.au.

Modules:

- Module 1: Vaccine history and importance
- Module 2: The immune system
- Module 3: Vaccine components
- Module 4: National Immunisation Program (NIP)
- Module 5: Pre-vaccination information
- Module 6: Vaccine preparation and administration
- Module 7: Post-vaccination care
- Module 8: Adverse event following immunisation (AEFI)
- Module 9: Vaccine development and safety
- Module 10: Responding to vaccine-hesitant patients
- Module 11: Special group - Vaccination and pregnancy
- Module 12: Special group - Vaccination for preterm infants
- Module 13: Special group - Aboriginal and Torres Strait Islander people
- Module 14: Special group - Vaccination for refugees

<https://central.csds.qld.edu.au/central/courses/415>

116

Qld Health Online Immunisation Courses

Immunisation Course 2: Vaccine management IC-VM

ONLINE



Register

Duration
2.5 hours

Certificate
Provided upon completion

Price (excludes GST)
Everyone \$0.00

Course description

This online course provides an overview of the importance of correct vaccine management in clinical settings from ordering to receiving vaccines, managing stock, maintaining cold chain and taking immediate actions in a cold chain breach.

You will learn about the roles and responsibilities of immunisation service providers in maintaining cold chain and about best practice risk management strategies to protect vaccines from a cold chain breach.

This course is for general education purposes only and does not lead to authorisation as an Immunisation Program Nurse.

If you experience any technical issues with the course, please read the FAQ's first here. If this does not resolve your issue, contact immunisation@health.qld.gov.au.

Modules:

- Module 1: The importance of vaccine management
- Module 2: Equipment for and monitoring of cold chain
- Module 3: Vaccine storage
- Module 4: Cold chain breach
- Module 5: Ordering and receiving vaccines

Related courses:

- Vaccine administration
- Immunisation data - recording and reporting
- Catch-up vaccinations

<https://central.csds.qld.edu.au/central/courses/420>

117

Qld Health Online Immunisation Courses

Immunisation Course 3: Immunisation data – recording and reporting IC-ID

ONLINE



Register

⌚ Duration

1.5 hours

📄 Certificate

Provided upon completion

💰 Price (excludes GST)

QLD Health

\$0.00

Course description

This online course provides an overview of the importance of recording and reporting immunisation data to the Australian Immunisation Register (AIR).

You will learn how you can access AIR to check immunisation records, how to report a medical exemption to immunisation to AIR and how to communicate with the register.

The course also explains the steps to reporting immunisation data in a consistent and accurate way and the documentation requirements post vaccination.

This course is for general education purposes only and does not lead to authorisation as an Immunisation Program Nurse.

If you experience any technical issues with the course, please read the FAQ's first here. If this does not resolve your issue, contact immunisation@health.qld.gov.au.

Modules

Module 1: Recording immunisation data

Module 2: Reporting immunisation data to the Australian Immunisation Register (AIR)

Related courses:

- Vaccine administration
- Vaccine management
- Catch-up vaccinations

<https://central.csds.qld.edu.au/central/courses/424>

118

Qld Health Online Immunisation Courses

Immunisation Course 4: Catch-up vaccinations IC-CV

ONLINE



Register

⌚ Duration

1.5 hours

📄 Certificate

Provided upon completion

💰 Price (excludes GST)

QLD Health

\$0.00

Course description

This online course provides an overview of the importance of up-to-date immunisations, the objectives of catch-up vaccinations and how the national due and overdue rules for immunisation are used by the Australian Immunisation Register (AIR) to determine an individual's immunisation status.

You will learn about the national due and overdue rules for immunisation and the steps to planning catch-up vaccinations.

This course is for general education purposes only and does not lead to authorisation as an Immunisation Program Nurse.

If you experience any technical issues with the course, please read the FAQ's first here. If this does not resolve your issue, contact immunisation@health.qld.gov.au.

Modules

Module 1: Catch-up vaccinations

Module 2: National due and overdue rules

Related courses:


- Vaccine administration
- Vaccine management
- Immunisation data – recording and reporting

Completion requirements

This course offers different pathways for clinical staff, administrative

<https://central.csds.qld.edu.au/central/courses/425>

119




Australian Government
Department of Health

Questions about vaccination


Download or order hard copy from:

<https://www.health.gov.au/resources/publications/questions-about-vaccination>



National Immunisation Program
A joint Australian, State and Territory Government Initiative


120



Academy School Education Programs

- Primary Connections
- Science by Doing
- reSolve: Mathematics by Inquiry
- Science videos and articles
- Immunisation, climate change and genetic modification
- The science of immunisation**
- The science of climate change
- Genetic modification
- History of Australian science

The science of immunisation



Measles alert


Watch later Share

Measles: everything you need to know

In 2014, Australia had eliminated measles—but it's back, and outbreaks are happening across the globe.

To explain why, the Australian Academy of Science has developed a series of videos and articles in partnership with the Australian Government Department of Health to explore why measles is such a serious disease, who is most at risk, and how you can make sure you're protected with vaccination.

You can find all our [videos and articles about measles here](#).



Immunisation saves lives

Watch later Share

<https://www.science.org.au/education/immunisation-climate-change-genetic-modification/science-immunisation>

121



122

Australian Government
Department of Health

[About us](#) [Ministers](#) [Media centre](#) [News](#) [Contact us](#)

Search this website

[Home](#) [Health topics](#) [Initiatives and programs](#) [Resources](#)

[Home](#) > [Health topics](#)

Immunisation

Immunisation is a simple, safe and effective way of protecting people against harmful diseases before they come into contact with them. Immunisation not only protects individuals, but also others in the community, by reducing the spread of preventable diseases.

Health professionals >
Find information that will help you deliver your service to your patients

Top tasks

- Learn about immunisation**
Find out all about immunisation, how it protects you and your family and how to get started.
- Check the National Immunisation Schedule**
The National Immunisation Program (NIP) Schedule sets out free vaccinations for children, school programs,
- Check immunisation history.**
Find out what vaccines you or your child has received and request an immunisation history statement.
- Get vaccinated**
Find out how to get vaccinated, what to expect and how to set immunisation reminders.

<https://www.health.gov.au/health-topics/immunisation>

123

NSLHD PHU Website

Immunisation

- Public Health Unit
- Environmental Health
- Immunisation
- Emergency Management
- Communicable Diseases
- Aged Care Facilities

Health information > Public Health Unit > Immunisation

The Public Health Unit provides general advice and information on adult and childhood immunisation to health care providers and members of the public. Staff also follow up reports of adverse reactions to vaccinations.

The Immunisation Team conducts the **Adolescent School Vaccination Program** which provides immunisations to school students for Diphtheria Tetanus Pertussis (Whooping Cough), Meningococcal ACWY, and Human Papillomavirus (HPV).

The Australian Department of Health **Immunise Australia Program** provides valuable information on all aspects of childhood immunisation. Their website includes information for the general public as well as for immunisation providers, including **The Australian Immunisation Handbook**, and the revised **National Immunisation Program**.

High school vaccination records

Vaccines offered in the school program since 2003 - no records are available prior to 2003.	
Human Papillomavirus vaccine offered to: <ul style="list-style-type: none">Female students in Years 10, 11 & 12 in 2007Female students in Years 7, 8, 9 & 10 in 2008All female students in Year 7 from 2009	<ul style="list-style-type: none">Male students in Year 9 in 2013 and 2014All male students in Year 7 from 2013All Year 7 students from 2013
Diphtheria/Tetanus/Pertussis vaccine offered to: <ul style="list-style-type: none">all high school students in 2004	Meningococcal ACWY vaccine offered to: <ul style="list-style-type: none">Year 11 & 12 students in 2017

<http://www.nslhd.health.nsw.gov.au/HealthInformation/PublicHealthUnit/Pages/Immunisation.aspx>

124



125